Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (APRIORI)
Phase II Study on Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (FOLFOXIRI/ Bevacizumab)
Sponsor: National Center for Tumor Diseases, Heidelberg
Terminated
recruiting inadequate
Other terminated trials from National Center for Tumor Diseases, Heidelberg
- GastroEsophageal Cancer · Phase PHASE2 · Oct 2013
- Adenocarcinomas of the Esophagogastric Junction · Phase PHASE2 · Dec 2012
More terminations from National Center for Tumor Diseases, Heidelberg
This PHASE2 trial investigates Colorectal Carcinoma and is currently terminated or withdrawn. National Center for Tumor Diseases, Heidelberg leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Center for Tumor Diseases, Heidelberg
- Pfizer
- Roche Pharma AG
For direct contact, visit the study record on ClinicalTrials.gov .